Biotech catalyst, news and analysis PDUFA tracker
Tickers reports and analysis
A full three-company edition covering an early wet-AMD durability signal, a $100 million gene-therapy financing that materially resets per-share ownership, and a traditional FDA approval that raises the evidence standard across the increasingly competitive IgA-nephropathy market.
Three biotech updates, three very different evidence problems: an early Parkinson’s disease signal moving toward Phase 2, a post hoc attempt to rescue a pulmonary sarcoidosis program after a missed Phase 3 endpoint, and an FDA-guided protocol optimization that may make a urology study faster and less expensive without yet proving efficacy.
Eli Lilly and AtaiBeckley signed a definitive merger agreement. ATAI holders are entitled to $6.75 per share in cash at closing plus a non-transferable CVR worth up to $2.50 per share tied to VLS-01 Phase 3 initiation and U.S. approval plus DEA rescheduling milestones for BPL-003 and VLS-01. The transaction carries approximately $2.8 billion of upfront equity value and up to $1.0 billion of contingent value.
Phase 2 CELIA produced one of the most intriguing tau signals yet seen in Alzheimer’s disease, but it did not settle the key issue: why did the lowest dose show the most persuasive cognitive benefit while higher doses failed to produce a stronger response?
$BIIB · $IONS
Alzheimer’s · Tau · Antisense
Merlintrader Biotech Radar Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO A deeper four-company edition covering an FDA delivery breakthrough in Alzheimer’s disease, a $1.5 billion lung-cancer licensing deal, a potentially treatment-changing organ-preservation…
Merlintrader Sector Deep Dive · Medical Robotics · Wearable Technology · Neurorehabilitation Beyond ReWalk: The Public Companies Competing for the Future of Exoskeletons and Neurorehabilitation — $LFWD $MYO $CHRN $APLD From the engineers who first turned robotic walking into a…
Biotech Radar July 13, 2026 $SNY $GH $PHVS Three-name biotech watch Biotech Radar July 13, 2026: Sanofi ($SNY), Guardant Health ($GH) and Pharvaris ($PHVS) Three distinct healthcare setups define today’s watch: a first-of-its-kind oncology delivery approval, a competitive read-through in…
Insider trading this week (July 6-10, 2026): the 20 biggest open-market buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts. Educational, no recommendations.
Today’s radar compares three very different catalyst structures: Chemomab’s proposed merger with Scipher Medicine and shift toward AI-guided rheumatoid arthritis development, CervoMed’s completed Phase 2a enrollment in nonfluent variant primary progressive aphasia, and AtaiBeckley’s completion of dosing in the VLS-01 Phase 2b Elumina trial ahead of a Q4 2026 topline readout.
Obesity drugs radar: Viking ($VKTX), Structure ($GPCR) and Skye ($SKYE) — three clinical-stage weight-loss stocks, their trials, cash positions and 2026 catalysts, with the Novo/Lilly landscape as context.
Merlintrader Deep Dive Published / updated: July 10, 2026 Biotech / Cell Therapy / Commercial Launch Analysis Mesoblast ($MESO) Deep Dive: Ryoncil Hits $36M in Q4 and $115M in FY2026 A full trader-focused analysis of Mesoblast’s first full fiscal year…
Ionis and AstraZeneca’s CARDIO-TTRansform trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy. The result does not erase Wainua’s existing polyneuropathy franchise, but it changes the near-term ATTR-CM competitive map and puts Alnylam and BridgeBio back at the center of investor attention.
Immunome (Nasdaq: IMNM) deep dive: the FDA accepted the varegacestat NDA for desmoid tumors with an April 28, 2027 PDUFA date, backed by strong Phase 3 RINGSIDE data, 82.7M cash and a broader ADC pipeline.
Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback.
Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question.
Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome.
Insider trading this week (June 29-July 3, 2026): the 20 biggest buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts.
Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
Abivax has moved from a speculative French biotech story to one of the most closely watched late-stage ulcerative colitis names in global healthcare. The June 29 ABTECT Maintenance Part 2 update did not simply add another dataset. It directly addressed the safety debate that had pressured the stock after the June 1 maintenance readout and pushed investors to reassess the risk/reward profile ahead of the planned U.S. NDA submission in Q4 2026.
The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
